Volver a Agenda
Session Chair(s)
Anna Fine, PHARMD, MS
Interim Director for ClinicalTrials.gov
National Institutes of Health (NIH), United States
Learning Objective : Describe innovative collaboration models with FDA for communicating safety information; Identify variety of programs as a result of the collaboration models; Recognize the FDA regulatory framework for collaborations and identify opportunity for future collaborations with FDA.
Speaker(s)
A New Vision: Leveraged Opportunities to Improve Public Health
Michael Duenas
American Optometric Association, United States
Chief Public Health Officer
Innovation in Collaboration: Lessons from Public-Private Partnerships
Amy Nadel
Medscape, United States
Executive Director, Professional Relationships
¿Tiene una cuenta?